Resverlogix (TSX: RVX) has received a rating update from a Wall Street analyst today. The company received a Buy rating from Roth Capital’s analyst Jotin Marango, with a C$10 price target.
According to TipRanks.com, Marango is a 1-star analyst with an average return of -5.1% and a 33.9% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
Read also: Here’s Why AcelRx Pharmaceuticals (ACRX) Stock Skyrocketed Today
Resverlogix has an analyst consensus of Moderate Buy, with a price target consensus of C$10.
Resverlogix’s market cap is currently C$574.9M and has a P/E ratio of 787.7. The company has a Price to Book ratio of -3.32.
Resverlogix Corp. is a clinical stage biotechnology company, which engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, peripheral artery, Orphan and Alzheimer’s diseases.
The company’s shares closed on Friday at C$3.24.
